Clinical Trial

Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of the study is to evaluate the safety and efficacy of tafasitamab and lenalidomide in participants with Large B Cell Lymphoma (LBCL) after axicabtagene ciloleucel (axi-cel) treatment. Participants will be asked to spend about 12 months in this study.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2024-12-30; most recent amendment 2026-03-30.
Trial Details
NCT Number NCT06760156
Lead Sponsor H. Lee Moffitt Cancer Center and Research Institute
Collaborators: Incyte Corporation
Conditions Large B-cell Lymphoma
Enrollment 28 participants
Start Date 2025-03-19
Primary Completion 2027-01 (estimated)
Study Completion 2028-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-03